Back to top
more

Moderna, Inc. (MRNA)

(Real Time Quote from BATS)

$199.52 USD

199.52
1,715,394

-2.95 (-1.46%)

Updated Jun 18, 2021 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (213 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for MRNA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Moderna, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 4,609 1,104 1,522 757 1,058
Receivables 1,391 5 13 13 14
Notes Receivable 0 0 0 0 0
Inventories 47 0 0 0 0
Other Current Assets 252 19 28 13 15
Total Current Assets 6,298 1,129 1,563 783 1,087
Net Property & Equipment 297 202 212 139 81
Investments & Advances 639 160 173 146 237
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 13 13 14 16 12
Total Assets 7,337 1,589 1,962 1,084 1,417
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 18 7 31 21 28
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 470 68 79 73 25
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 3,901 68 113 98 110
Total Current Liabilities 4,389 143 223 191 163
Mortgages 0 0 0 0 0
Deferred Taxes/Income 177 139 175 251 399
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 110 39 0 0 0
Other Non-Current Liabilities 2 0 34 1,194 1,190
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 4,775 415 432 1,636 1,752
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 4,802 2,669 2,538 72 31
Retained Earnings -2,244 -1,496 -1,007 -622 -366
Other Equity 3 2 -1 -1 -0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,561 1,175 1,530 -551 -335
Total Liabilities & Shareholder's Equity 7,337 1,589 1,962 1,084 1,417
Total Common Equity 2,561 1,175 1,530 -551 -335
Shares Outstanding 395.70 336.50 328.90 NA NA
Book Value Per Share 6.47 3.49 4.65 0.01 0.00

Fiscal Year End for Moderna, Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Assets          
Cash & Equivalents 7,735 4,609 3,277 2,718 1,219
Receivables 3,210 1,391 191 33 7
Notes Receivable 0 0 0 0 0
Inventories 494 47 0 0 0
Other Current Assets 264 252 109 45 24
Total Current Assets 11,703 6,298 3,577 2,797 1,250
Net Property & Equipment 372 297 277 230 202
Investments & Advances 468 639 692 355 502
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 50 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 12 13 13 12 13
Total Assets 12,694 7,337 4,651 3,486 2,068
Liabilities & Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 8 18 21 19 11
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 753 470 209 89 55
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 7,680 3,901 1,244 54 69
Total Current Liabilities 8,441 4,389 1,474 162 135
Mortgages 0 0 0 0 0
Deferred Taxes/Income 179 177 208 208 143
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 138 110 109 68 39
Other Non-Current Liabilities 2 2 1 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 8,856 4,775 1,891 539 427
Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 4,860 4,802 4,726 4,676 3,268
Retained Earnings -1,023 -2,244 -1,971 -1,737 -1,621
Other Equity 1 3 5 8 -6
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 3,838 2,561 2,760 2,947 1,641
Total Liabilities & Shareholder's Equity 12,694 7,337 4,651 3,486 2,068
Total Common Equity 3,838 2,561 2,760 2,947 1,641
Shares Outstanding 400.50 395.70 395.70 371.20 329.00
Book Value Per Share 9.58 6.47 6.97 7.94 4.99